MetLife Investment Management LLC Grows Position in Doximity, Inc. (NASDAQ:DOCS)

MetLife Investment Management LLC lifted its position in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 11.5% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 72,540 shares of the company's stock after purchasing an additional 7,476 shares during the period. MetLife Investment Management LLC's holdings in Doximity were worth $3,873,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in DOCS. Global Retirement Partners LLC grew its holdings in Doximity by 468.1% in the 4th quarter. Global Retirement Partners LLC now owns 534 shares of the company's stock worth $29,000 after acquiring an additional 440 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Doximity by 69.1% during the fourth quarter. UMB Bank n.a. now owns 575 shares of the company's stock worth $31,000 after purchasing an additional 235 shares during the period. Larson Financial Group LLC grew its stake in shares of Doximity by 49.4% in the fourth quarter. Larson Financial Group LLC now owns 756 shares of the company's stock worth $40,000 after purchasing an additional 250 shares during the last quarter. Optimum Investment Advisors purchased a new position in Doximity during the 4th quarter valued at about $43,000. Finally, Morse Asset Management Inc purchased a new stake in Doximity in the 3rd quarter worth approximately $46,000. 87.19% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. The Goldman Sachs Group boosted their target price on Doximity from $58.00 to $80.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Truist Financial decreased their price objective on shares of Doximity from $65.00 to $58.00 and set a "hold" rating for the company in a report on Thursday, April 10th. KeyCorp cut their target price on shares of Doximity from $83.00 to $70.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 16th. Morgan Stanley reduced their price target on shares of Doximity from $71.00 to $60.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 24th. Finally, Leerink Partners upgraded shares of Doximity from a "market perform" rating to an "outperform" rating and raised their price objective for the stock from $60.00 to $90.00 in a report on Friday, February 7th. Eleven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $65.39.

Insider Buying and Selling at Doximity

In other news, Director Timothy S. Cabral sold 20,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the sale, the director now owns 6,360 shares in the company, valued at $366,463.20. This represents a 75.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 37.40% of the stock is owned by company insiders.

Doximity Stock Performance

Shares of DOCS traded up $1.27 during trading hours on Thursday, hitting $58.15. The company had a trading volume of 601,349 shares, compared to its average volume of 1,988,736. The stock has a market capitalization of $10.86 billion, a price-to-earnings ratio of 58.27, a P/E/G ratio of 4.10 and a beta of 1.41. The firm has a fifty day moving average price of $59.64 and a 200-day moving average price of $56.38. Doximity, Inc. has a 52-week low of $22.96 and a 52-week high of $85.21.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.